The 15kDa selenoprotein and thioredoxin reductase 1 promote colon cancer by different pathways

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Tsuji, Petra A ^a   Carlson, Bradley A ^b   Yoo, Min Hyuk ^b   Naranjo Suarez, Salvador ^b   Xu, Xue Ming ^b,e   He, Yiwen ^c   Asaki, Esther ^c   Seifried, Harold E ^b   Reinhold, William C ^b   Davis, Cindy D ^b   Gladyshev, Vadim N ^d   Hatfield, Dolph L ^b  

^a TOWSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e GeneCopoeia Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; SELENOPROTEIN; SELENOPROTEIN 15; STAT1 PROTEIN; THIOREDOXIN REDUCTASE 1; UNCLASSIFIED DRUG; WNT PROTEIN; SEP15 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR PROMOTION; ANIMAL; BAGG ALBINO MOUSE; COLON TUMOR; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION PROFILING; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; SELENOPROTEINS; THIOREDOXIN REDUCTASE 1;

EID: 84929497335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124487     Document Type: Article

References (50)

1. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society, 2013.
2. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003; 91: 608-612. PMID: 12699469
3. Jao SW, Shen KL, Lee WP, Ho YS. Effect of selenium on 1,2-dimethylhydrazine-induced intestinal cancer in rats. Dis Colon Rectum. 1996; 39: 628-631. PMID: 8646947
4. Almondes KG, Leal GV, Cozzolino SM, Philippi ST, Rondó PH. The role of selenoproteins in cancer. Rev Assoc Med Bras. 2010; 56: 484-488. PMID: 20835649
5. Apostolou S, Klein JO, Mitsuuchi Y, Shetler JN, Poulikakos PL, Jhanwar SC, et al. Growth inhibition and induction of apoptosis in mesothelioma cells by selenium and dependence on selenoprotein SEP15 genotype. Oncogene. 2004; 23: 5032-5040. PMID: 15107826
6. Jablonska E, Gromadzinska J, Sobala W, Reszka E, Wasowicz W. Lung cancer risk associated with selenium status is modified in smoking individuals by Sep15 polymorphism. Eur J Cancer. 2008; 47: 47-54.
7. Tsuji PA, Carlson BA, Naranjo-Suarez S, Yoo MH, Xu X, Fomenko DE, et al. Knockout of the 15 kDa selenoprotein protects against chemically-induced aberrant crypt formation in mice. PLoS One. 2012; 7: e50574. doi: 10.1371/journal.pone.0050574 PMID: 23226526
8. Yoo MH, Carlson BA, Tsuji PA, Tobe R, Naranjo-Suarez S, Lee BJ, et al. Selenoproteins harboring a split personality in both preventing and promoting cancer. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium - Its molecular biology and role in human health. 3rd ed. New York: Springer Science + Business Media, LLC; 2012.
9. Brigelius-Flohé R, Müller M, Lippmann D, Kipp AP. The yin and yang of nrf2-regulated selenoproteins in carcinogenesis. Int J Cell Biol. 2012; 2012: 486147. doi: 10.1155/2012/486147 PMID: 22654914
10. Peters U, Chatterjee N, Hayes RB, Schoen RE, Wang Y, chanock SJ, et al. Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1144-1154. doi: 10.1158/1055-9965.EPI-07-2947 PMID: 18483336
11. Carlson BA, Yoo MH, Tobe R, Mueller C, Naranjo-Suarez S, Hoffman VJ, et al. Thioredoxin reductase 1 protects against chemically induced hepatocarcinogenesis via control of cellular redox homeostasis. Carcinogenesis. 2012; 33: 1806-1813. doi: 10.1093/carcin/bgs230 PMID: 22791808
12. Kasaikina MV, Hatfield DL, Gladyshev VN. Understanding selenoprotein function and regulation through the use of rodent models. Biochim Biophys Acta. 2012;1823 1633-1642. doi: 10.1016/j.bbamcr.2012.02.018 PMID: 22440326
13. Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins: Molecular pathways and physiological roles. Physiological Reviews. 2014; 94: 739-777. doi: 10.1152/physrev.00039.2013 PMID: 24987004
14. Arnér ES, Holmgren A. The thioredoxin system in cancer. Semin Cancer Biol. 2006; 16: 420-426. PMID: 17092741
15. Yoo MH, Xu XM, Carlson BA, Patterson AD, Gladyshev VN, Hatfield DL. Targeting thioredoxin reductase 1 reduction in cancer cells inhibits self-sufficient growth and DNA replication. PLOS One. 2007; 2: e1112. PMID: 17971875
16. Korotkov KV, Kumaraswamy E, Zhou Y, Hatfield DL, Gladyshev VN. Association between the 15-kDa selenoprotein and UDP-glucose:glycoprotein glucosyltransferase in the endoplasmic reticulum of mammalian cells. J Biol Chem. 2001; 276: 15330-15336. PMID: 11278576
17. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotypes and tumorigenicity of lung carcinoma cells. J Biol Chem 2006; 281: 13005-13008. PMID: 16565519
18. Irons R, Tsuji PA, Carlson BA, Ouyang P, Yoo MH, Xu XM, et al. Deficiency in the 15 kDa selenoprotein inhibits tumorigenicity and metastasis of colon cancer cells. Cancer Prev Res. 2010; 3: 630-639. doi: 10.1158/1940-6207.CAPR-10-0003 PMID: 20388823
19. Tsuji PA, Naranjo-Suarez S, Carlson BA, Tobe R, Yoo MH, Davis CD. Deficiency in the 15 kDa selenoprotein inhibits colon cancer cell growth. Nutrients. 2012; 3: 805-817.
20. Kumaraswamy E, Korotkov KV, Diamond AM, Gladyshev VN, Hatfield DL. Genetic and functional analysis of mammalian Sep15 selenoprotein. Methods Enzymol. 2002; 347: 187-197. PMID: 11898406
21. Wright ME, Diamond AM. Polymorphisms in selenoprotein genes and cancer. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium - Its molecular biology and role in human health. 3rd ed. New York: Springer Science + Business Media, LLC; 2012.
22. Xu XM, Yoo MH, Carlson BA, Gladyshev VN, Hatfield DL. Simultaneous knockdown of the expression of two genes using multiple shRNAs and subsequent knock-in of their expression. Nat Protoc. 2009; 4: 1338-1348. doi: 10.1038/nprot.2009.145 PMID: 19713955
23. Yoo MH, Carlson BA, Tsuji PA, Irons R, Gladyshev VN, Hatfield DL. Alteration of thioredoxin reductase 1 levels in elucidating cancer etiology. Methods Enzymol. 2010; 474: 255-275. doi: 10.1016/S0076-6879(10)74015-5 PMID: 20609915
24. Holmgren A, M. B. Thioredoxin and thioredoxin reductase. Methods Enzymol. 1995; 252: 199-208. PMID: 7476354
25. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, et al. CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set. Cancer Res. 2012; 72: 3499-3511. doi: 10.1158/0008-5472.CAN-12-1370 PMID: 22802077
26. Hsieh CM, Yoshizumi M, Endege WO, Kho CJ, Jain MK, Kashiki S, et al. APEG-1, a novel gene preferentially expressed in aortic smooth muscle cells, is down-regulated by vascular injury. J Biol Chem. 1996; 271: 17354-17359. PMID: 8663449
27. Hatfield DL, Tsuji PA, Carlson BA, Gladyshev VN. Selenium and selenocysteine: roles in cancer, health, and development. Trends in Biochemical Sciences. 2014; 39: 112-120. doi: 10.1016/j.tibs.2013.12.007 PMID: 24485058
28. Clark LC, Combs GFJ, Turnbull BW, Slate E, Chalker D, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA. 1996; 276: 1957-1963. PMID: 8971064
29. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev. 2002; 11: 630-639. PMID: 12101110
30. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009: 1.
31. Irons R, Carlson BA, Hatfield DL, Davis CD. Both selenoproteins and low molecular weight selenocompounds reduce colon cancer risk in mice with genetically impaired selenoprotein expression. J Nutr 2006; 135: 1311-1317.
32. Kasaikina MV, Fomenko DE, Labunskyy VM, Lachke SA, Qiu W, Moncaster JA, et al. Roles of the 15-kDa selenoprotein (Sep15) in redox homeostasis and cataract development revealed by the analysis of Sep 15 knockout mice. J Biol Chem. 2011; 286: 33203-33212. doi: 10.1074/jbc.M111.259218 PMID: 21768092
33. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 2012; 143: 1660-1669. doi: 10.1053/j.gastro.2012.09.002 PMID: 22974708
34. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998; 27: 273-278. PMID: 9425947
35. Pensa S, Regis G, Boselli D, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis: two sides of the same coin? In: Stephanou A, editor. JAK-STAT Pathway in Disease. Austin, TX: Landis Bioscience; 2009.
36. Lee SC, Chan J, Clement MV, Pervaiz S. Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop. Proteomics. 2006; 6: 2386-2394. PMID: 16518869
37. Chan JY, Phoo MS, Clement MV, Pervaiz S, Lee SC. Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther. 2008; 7: 1308-1312.
38. Santin I, Moore F, Grieco FA, Marchetti P, Brancolini C, Eizirik DL. USP18 is a key regulator of the interferon-drivengene network modulating pancreatic beta-cell inflammation and apoptosis. Cell Death and Disease. 2012; 3: e419. doi: 10.1038/cddis.2012.158 PMID: 23152055
39. Ma X, Hu J, Lindner DJ, Kalvakolanu DV. Mutational analysis of human thioredoxin reductase 1. Effects on p53-mediated gene expression and interferon and retinoic acid-induced cell death. J Biol Chem. 2002; 277: 22460-22468. PMID: 11953436
40. Moos PJ, Edes K, Cassidy P, Massuda E, Fitzpatrick FA. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J Biol Chem. 2003; 278: 745-750. PMID: 12424231
41. Patterson AD, Carlson BA, Li F, Bonzo JA, Yoo MH, Krausz KW, et al. Disruption of thioredoxin reductase 1 protects mice from acute Acetaminophen-induced hepatotoxicity through enhanced NRF2 activity. Chem Res Toxicol. 2013; 26: 1088-1096. doi: 10.1021/tx4001013 PMID: 23697945
42. Gasdaska JR, Berggren M, Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. 1995; 6: 1643-1650. PMID: 9019170
43. Suvorova ES, Lucas O, Weisend CM, Rollins MF, Merrill GF, Capecchi MR, et al. Cytoprotective Nrf2 pathway is induced in chronically txnrd 1-deficient hepatocytes. PLoS One. 2009; 4: e6158. doi: 10.1371/journal.pone.0006158 PMID: 19584930
44. Fodde R. The APC gene in colorectal cancer. Eur J Cancer Prev. 2002; 38: 867-871.
45. Wang JW, Jiang YN, Huang CY, Huang PY, Huang MC, Cheng WT, et al. Proliferin enhances microvilli formation and cell growth of neuroblastoma cells. Neurosci Res. 2006 56: 80-90. PMID: 16876275
46. Wang XY, Yin Y, Yuan H, Sakamaki T, Okano H, Glazer RI. Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. Mol Cell Biol. 2008 28: 3589-3599. doi: 10.1128/MCB.00040-08 PMID: 18362162
47. Juuti A, Nordling S, Louhimo J, Lundin J, Haglund C. Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol. 2004; 57: 1151-1155. PMID: 15509674
48. Kressner U, Lindmark G, Tomasini-Johansson B, Bergström R, Gerdin B, Påhlman L, et al. Stromal tenascin distribution as a prognostic marker in colorectal cancer. Br J Cancer. 1997; 76: 526-530. PMID: 9275031
49. Kipp A, Banning A, van Schothorst EM, Méplan C, Schomburg L, Evelo C, et al. Four selenoproteins, protein synthesis, and Wnt signaling are particularly sensitive to limited selenium intake in mouse colon. Mol Nutr Food Res. 2009; 53: 1561-1572. doi: 10.1002/mnfr.200900105 PMID: 19810021
50. Hatfield DL, Gladyshev VN. The Outcome of Selenium and Vitamin E Cancer Prevention Trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv. 2009; 9: 18-21. doi: 10.1124/mi.9.1.6 PMID: 19299660